Attachment 2i_I.9- GONOCOCCAL (GC) ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) IN JURISDICTION- AEPMR

Status: The document is viewable, but some background extraction is still pending.

Queue: Repair is in progress, but the document is still incomplete and remains in the worker queue. (priority 60 · attempts 1 · next 2026-06-19 14:58:50)

Missing: html

Download: Source copy (docx) | pdf

Annual Evaluation and Performance Measurement Report (I.9- GONOCOCCAL (GC) ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) IN JURISDICTION)
Annually, each funded laboratory is required to report to CDC evaluation and performance measures. Data are used to indicate progress made toward program outcomes. These summary reports have to be uploaded to the ELC CAMP at the end of each funding year. Required performance measures are listed below.
    1. Proportion of isolates transported per program guidance to CDC:
    a. Numerator: Number of isolates transported to CDC
    b. Denominator: Total number of isolates requested
    c. Calculated: Percent of isolates transported upon request to CDC
    2. Proportion of AST results reported to submitters within 3 weeks of submission:
    a. Numerator: Number of AST results reported to sentinel sites within 3 weeks of submission
    b. Denominator: Number of GC isolates received at AR Lab Network
    c. Calculated: Percentage of AST results reported to sentinel sites within 3 weeks of submission

    3. Proportion of contaminated specimens submitted by each laboratory, by site:
Contaminated Specimens
Site:
Submitting Laboratory Site Name (pulled from question 1)
Number of contaminated specimens submitted
Number of Specimens submitted (pulled from question 1)
Calculated: Percent of contaminated specimens submitted
1




2





    4. Describe any challenges you've faced with conducting AST and/or reporting results back to submitting laboratories within 3 weeks of submission.
    5. Proportion of isolates with AST results for zoliflodacin:
        a. Numerator: Number of isolates with zoliflodacin AST results.
        b. Denominator: Total number of isolates submitted for AST.
        c. Calculated: Percentage of isolates with zoliflodacin AST results.
    6. Proportion of isolates with AST results for doxycycline:
        a. Numerator: Number of isolates with doxycycline AST results.
        b. Denominator: Total number of isolates submitted for AST.
        c. Calculated: Percentage of isolates with doxycycline AST results.
    7. Proportion of isolates with AST results for ertapenem:
        a. Numerator: Number of isolates with ertapenem AST results.
        b. Denominator: Total number of isolates submitted for AST.
        c. Calculated: Percentage of isolates with ertapenem AST results.
    8. Total number of laboratory proficient in GC AST methods.
    9. Total number of Etest AST requests received
        a. Number of different submitters

    10.  Number and proportion of types of samples received by anatomical site for Etest

Anatomical Site
Number of Etest AST requests
Number of Etests with results reported to submitter







11.  Proportion of 'Alert' isolates:
a. Numerator: Number of isolates with 'Alert' minimum inhibitory concentrations (MICs)
b. Denominator: Number of isolates tested for antimicrobial susceptibility
c. Calculated: Percentage of isolates with 'Alert' MICs of all isolates tested for antimicrobial susceptibility